## Clinical Overview of Immune Thrombocytopenic Purpura (ITP) Immune thrombocytopenic purpura (ITP), formerly known as idiopathic thrombocytopenic purpura, is an acquired autoimmune hematological disorder characterized by a low peripheral blood platelet count (thrombocytopenia) defined as <100 x 10⁹/L. This condition occurs in the absence of any other underlying cause or identifiable pathology that could account for the low platelet count. ITP is broadly categorized based on duration: 'newly diagnosed' (less than 3 months), 'persistent' (3 to 12 months), and 'chronic' (lasting more than 12 months). While the condition can affect individuals of all ages, it frequently presents as an acute, self-limiting disorder in children following a viral infection, whereas in adults, it more commonly follows a chronic, indolent course. ### Pathophysiology The primary pathophysiological mechanism of ITP involves the immune-mediated destruction of platelets and the inhibition of platelet production. B-cells produce autoantibodies, typically of the immunoglobulin G (IgG) class, that target specific platelet surface glycoproteins, most commonly the GPIIb/IIIa or GPIb/IX complexes. Once these platelets are coated with autoantibodies, they are recognized by Fc receptors on splenic macrophages and other cells of the reticuloendothelial system, leading to their premature clearance and destruction in the spleen and liver. Furthermore, these same autoantibodies can target megakaryocytes—the precursors of platelets—in the bone marrow, impairing their maturation and decreasing the overall rate of platelet production. T-cell-mediated cytotoxicity against platelets and megakaryocytes also plays a significant role in the pathogenesis of the disease. ### Clinical Presentation and Diagnosis Patients with ITP often present with mucocutaneous bleeding symptoms. These include petechiae (tiny, flat, red or purple spots on the skin), purpura (larger bruises), and ecchymoses. Mucosal bleeding manifestations such as epistaxis (nosebleeds), gingival bleeding, and menorrhagia (heavy menstrual periods) are also frequent. Life-threatening complications, such as intracranial hemorrhage or significant gastrointestinal bleeding, are rare but remain a primary concern when platelet counts drop below 10-20 x 10⁹/L. Diagnosis is largely one of exclusion. Clinicians must rule out secondary causes of thrombocytopenia, such as drug-induced reactions, systemic lupus erythematosus (SLE), chronic lymphocytic leukemia (CLL), and infections like HIV, Hepatitis C, or Helicobacter pylori. A peripheral blood smear is essential to rule out pseudothrombocytopenia (platelet clumping) and other hematologic malignancies. ### Standard of Care and Management The management of ITP is highly individualized, focusing on achieving a safe platelet count to prevent major bleeding rather than normalizing the count. For newly diagnosed adults with platelet counts <30 x 10⁹/L or those with active bleeding, first-line therapy typically consists of corticosteroids (prednisone or high-dose dexamethasone), intravenous immunoglobulin (IVIG), or Rh0(D) immune globulin. In cases where ITP becomes persistent or chronic, second-line options include thrombopoietin receptor agonists (TPO-RAs) like eltrombopag or romiplostim, rituximab (a monoclonal antibody against CD20), and splenectomy. Splenectomy remains the most effective long-term treatment for achieving remission, though its use has decreased due to the availability of effective medical alternatives.